1. Home
  2. ELDN vs BLFY Comparison

ELDN vs BLFY Comparison

Compare ELDN & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • BLFY
  • Stock Information
  • Founded
  • ELDN 2004
  • BLFY 1939
  • Country
  • ELDN United States
  • BLFY United States
  • Employees
  • ELDN N/A
  • BLFY N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • BLFY Commercial Banks
  • Sector
  • ELDN Health Care
  • BLFY Finance
  • Exchange
  • ELDN Nasdaq
  • BLFY Nasdaq
  • Market Cap
  • ELDN 178.4M
  • BLFY 204.2M
  • IPO Year
  • ELDN N/A
  • BLFY N/A
  • Fundamental
  • Price
  • ELDN $2.72
  • BLFY $8.86
  • Analyst Decision
  • ELDN Strong Buy
  • BLFY Hold
  • Analyst Count
  • ELDN 2
  • BLFY 2
  • Target Price
  • ELDN $12.50
  • BLFY $11.00
  • AVG Volume (30 Days)
  • ELDN 198.6K
  • BLFY 41.0K
  • Earning Date
  • ELDN 08-18-2025
  • BLFY 07-23-2025
  • Dividend Yield
  • ELDN N/A
  • BLFY N/A
  • EPS Growth
  • ELDN N/A
  • BLFY N/A
  • EPS
  • ELDN N/A
  • BLFY N/A
  • Revenue
  • ELDN N/A
  • BLFY $41,228,000.00
  • Revenue This Year
  • ELDN N/A
  • BLFY $20.14
  • Revenue Next Year
  • ELDN N/A
  • BLFY $20.20
  • P/E Ratio
  • ELDN N/A
  • BLFY N/A
  • Revenue Growth
  • ELDN N/A
  • BLFY N/A
  • 52 Week Low
  • ELDN $2.30
  • BLFY $8.30
  • 52 Week High
  • ELDN $5.54
  • BLFY $11.48
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 35.43
  • BLFY 40.92
  • Support Level
  • ELDN $2.76
  • BLFY $8.71
  • Resistance Level
  • ELDN $2.90
  • BLFY $8.94
  • Average True Range (ATR)
  • ELDN 0.16
  • BLFY 0.22
  • MACD
  • ELDN -0.03
  • BLFY -0.01
  • Stochastic Oscillator
  • ELDN 4.39
  • BLFY 42.15

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

Share on Social Networks: